Press Releases

Nov 7, 2018

New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
Nov 6, 2018

FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Oct 31, 2018

Sanofi Q3 2018 Performance Confirms Return to Growth
- Photos 4
Oct 30, 2018

FDA grants priority review for Sanofi's dengue vaccine candidate
Oct 19, 2018

FDA approves asthma indication for Dupixent® (dupilumab)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

Show per page

Print
Email page
RSS